Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement
EASL LiverTree™, Rohit Loomba, 207337
Does the bile acid receptor TGR5 play a role in Kupffer cell response during Alcoholic Liver Disease?
EASL LiverTree™, Madeleine Spatz, 207339
Secreted ectodomain of SIGLEC-9 and MCP-1 ameliorate acute liver failure in rats by altering bone marrow macrophage polarity
EASL LiverTree™, Takanori Ito, 207354
Elevated programmed death ligand 2 (PDL2) in macrophages of BALB/c mice model of liver fibrosis associated with decreased CD80 and IL12 expressions 
EASL LiverTree™, Johnny Amer, 207355
Impact of acute hepatic porphyrias on quality of life and work loss: an analysis of EXPLORE natural history study
EASL LiverTree™, Sonalee Agarwal, 207372
Trends in healthcare utilization in the United States and Europe associated with patient with acute hepatic porphyria with recurrent attacks in EXPLORE: a prospective, multinational natural history study of patients with acute hepatic porphyria
EASL LiverTree™, Sonalee Agarwal, 207373
PREVALENCE AND PREDICTIVE FACTORS OF HEPATIC NODULES IN PATIENTS WITH FONTAN SURGERY: THE VALDIG FONLIVER STUDY
EASL LiverTree™, Enrique Rodríguez-Santiago, 207374
The effect of re-exposure to somatostatin analogues in patients with polycystic liver disease
EASL LiverTree™, René van Aerts, 207375
Clinicalpresentation and outcome of Wilson’s disease patients in a monocentric cohort ofliver reference center
EASL LiverTree™, Rodolphe Sobesky, 207387
The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease
EASL LiverTree™, Thomas Damgaard Sandahl, 207390
The global prevalence of lysosomal acid lipase deficiency estimated by meta-analysis of pathogenic mutations and functional variants from next-generation sequencing data
EASL LiverTree™, Anna Carter, 207391
Liver disease in a cohort of patients with Gaucher disease from Southern Brazil: a cross-sectional study. 
EASL LiverTree™, Rodrigo Starosta, 207393
Characteristics associated with non-response to ursodeoxycholic acid in primary biliary cholangitis
EASL LiverTree™, Teresa Dias, 207394
Predictions from a very hard liver: the role of liver stiffness in alcoholic hepatitis  
EASL LiverTree™, Petra Fischer, 207408
Soluble serum vascular adhesion protein (sVAP)-1: a new biomarker in primary sclerosing cholangitis?
EASL LiverTree™, Francesca Saffioti, 207409
Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection  
EASL LiverTree™, SHU YEIN HO, 207410
Enhanced Liver Fibrosis (ELF) Test predicts liver-related outcomes in postmenopausal women with risk factors in the community
EASL LiverTree™, Paul Trembling, 207411
Liver function assessment using magnetic resonance imaging with gadoxetic acid administration
EASL LiverTree™, Christina Levick, 207425
Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity
EASL LiverTree™, Christina Levick, 207426
Overestimation and underestimation of liver fibrosis stage classification assessed by transient elastography and two-dimensional shear wave ultrasound
EASL LiverTree™, sang gyune kim, 207427
Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis
EASL LiverTree™, Tomi Jun, 207428
Preoperative biliary drainage reverses cholestasis-associated inflammatory and fibrotic gene signatures in patients with perihilar cholangiocarcinoma
EASL LiverTree™, Rowan van Golen, 207447
Distinct functions of phosphorylated and un-phosphorylated STAT1 in hepatocellular carcinoma
EASL LiverTree™, Buyun Ma, 207448
High fat diet induces a tumor like metabolism in the liver
EASL LiverTree™, joao duarte, 207449
Nrf2 pathway plays an important role in the development of hepatocellular carcinoma:  the gene expression signature of Nrf2 observed in a rat hepatocarcinogenesis model
EASL LiverTree™, Carlos David López, 207450
Difference of gene mutational profile among viral- and non-viral HCC with  or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration
EASL LiverTree™, Fukiko Kawai-Kitahata, 207464
Therapeutics of cell-specific MAPK modulation in chronic liver disease using (siJNK2) nanodelivery
EASL LiverTree™, Marius Maximilian Woitok, 207465
Deletion of MyD88 in non-parenchymal cells, but not in parenchymal cells attenuates the progression of hepatocellular carcinoma
EASL LiverTree™, Antje Mohs, 207466
Interventional gene targeting of cell cycle regulators identifies Cyclin E1 as a suitable target for attenuating hepatocellular carcinoma progression
EASL LiverTree™, Roland Sonnatg, 207467
The anti-inflammatory receptor TREM2 halts the generation of HCC in mice through the inhibition of liver inflammation and hepatocyte proliferative responses
EASL LiverTree™, María Jesús Perugorria, 207483
Functional genomics identified actin cytoskeleton remodeling required for the hypoxia-mediated EMT: a mechanistic link of tumor size to metastasis
EASL LiverTree™, Sen-Yung Hsieh, 207484
The HDAC inhibitorbelinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors ina murine hepatocellular carcinoma model
EASL LiverTree™, Pablo Sarobe, 207485
OBETICHOLIC ACID, A FXR AGONST, INHIBITS THE CANCEROGENIC POTENTIAL OF PRIMARY HUMAN CHOLANGIOCARCINOMA (CCA) CELLS CULTURES
EASL LiverTree™, Sabina Di Matteo, 207487
The role of IL-6 signaling pathway in cholangiocarcinoma
EASL LiverTree™, Ruben Plentz, 207500
A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma
EASL LiverTree™, Riccardo Patti, 207502
Disrupted cholesterol synthesis leads to female prevalent hepatocellular carcinoma in transgenic mice
EASL LiverTree™, Kaja Blagotinšek Cokan, 207503
Impact of Trp53  on tumor heterogeneity in the background of liver fibrosis
EASL LiverTree™, Umesh Tharehalli Mathada, 207504
Assessing Baveno VI criteria with a new point-shear wave elastography technique: the BAVElastPQ study
EASL LiverTree™, Giulia Gibiino, 207520
The efficacy and clinical outcome of transjugular intrahepatic portosystemic shunts (TIPS) in the management of ectopic variceal bleeding: a multicenter retrospective study
EASL LiverTree™, Rosalie Oey, 207521
Outcomes of pregnancy in women with cirrhosis - a national, population-based cohort study
EASL LiverTree™, Hannes Hagström, 207522
THE AMELIORATION OF MUSCLE WASTING LEADS TO THE IMPROVEMENT OF COGNITIVE IMPAIRMENT AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT: A PROOF OF CONCEPT THAT SARCOPENIA AND HEPATIC ENCEPHALOPATHY ARE CAUSALLY RELATED
EASL LiverTree™, Stefania Gioia, 207537
NON CIRRHOTIC PORTAL HYPERTENSION SECONDARY TO OXALIPLATIN THERAPY : INCIDENCE AND PRESENTATION 
EASL LiverTree™, Stefania Gioia, 207538
The Cost-Effectiveness of Albumin in the Treatment of Decompensated Cirrhosis in Italy, Spain and Germany 
EASL LiverTree™, Paolo Caraceni, 207539
Non-selective beta-blockers increase liver mortality when MELD is ≥12 in a prospective 5 year follow-up cohort of alcoholic cirrhosis
EASL LiverTree™, Paul Cales, 207552
Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort
EASL LiverTree™, Apurva Yeluru, 207553
Prior or On-treatment Infection Does Not Affect Response to Treatment or Survival in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
EASL LiverTree™, Florence Wong, 207554
Anticoagulant treatment for atrial fibrillation and decompensation rate in patients with liver cirrhosis 
EASL LiverTree™, Irina Girleanu, 207555
Varices on CT is the surrogate of clinically significant portal hypertension and can predict survival in patients with cirrhosis
EASL LiverTree™, Dong Ho Lee, 207569
Predictors of Endoscopic High Risk EsophagealVarices in Compensated Cirrhosis: Can we Avoid Fibroscan?
EASL LiverTree™, Julian Hercun, 207570
Second-look endoscopy and prolonged use of proton pump inhibitor and octreotide after variceal ligation reduce early bleeding rate in cirrhosis with large gastroesophageal varices: a single-blinded, single-centered and randomized controlled trial
EASL LiverTree™, Anjiang Wang, 207572
Uncontrolled diabetes increases all causes of mortality and particularly cardiovascular death in patients with cirrhosis
EASL LiverTree™, Maria de Fatima Higuera de la Tijera, 207573
Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant
EASL LiverTree™, Brooke Chapman, 207588
Dynamic Visual Processing in Patients with Decompensated Cirrhosis
EASL LiverTree™, Katherine Wong, 207589
The physical component of the SF-36 Quality of Life tool is an independent predictor of mortality in patients with severe ascites
EASL LiverTree™, Stewart Macdonald, 207590
Clinical frailty scale as a novel tool predicts unplanned hospitalisation and/or death in outpatients with cirrhosis.
EASL LiverTree™, ANIRUDDHA PRATAP SINGH, 207591
Screening of esophagogastric varices: performance of the 'Expanded Baveno VI criteria' and the 'platelet 150/MELD 6' strategy in all etiology compensated advanced chronic liver disease
EASL LiverTree™, giulia tosetti, 207605
Combined elastin and collagen proportionate area (ECPA) sub-classifies cirrhosis and predicts clinical outcomes
EASL LiverTree™, Avik Majumdar, 207606
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is highly effective in patients with a MELD score < 20 and does not require routine Doppler ultrasound follow-up
EASL LiverTree™, Koos de Wit, 207607
Efficacy of Liver Stiffness Measurement and Platelet Count in Screening for High Grade Varies in Patients with Cirrhosis.
EASL LiverTree™, ashish agarwal, 207608
Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures. 
EASL LiverTree™, Javier Ampuero, 207623
Four years outcomes of Baveno VI low risk cirrhotic patients
EASL LiverTree™, Priscila Pollo Flores, 207624
A novel sonographic parameter for the quantification of muscle mass in cirrhosis
EASL LiverTree™, Kazufumi Kobayashi, 207625
Repeated episodes of acute kidney injury (AKI) on the transplant waiting list: Impact on post-liver transplantation renal and patient outcomes
EASL LiverTree™, Shuet Fong Neong, 207626
Impact of adrenal dysfunction on psoas muscle thickness assessed by computed tomography in patients with liver cirrhosis 
EASL LiverTree™, Graziella Privitera, 207639
Drug-induced encephalopathy in cirrhotic patients with neurological symptoms: a metabolomic study.
EASL LiverTree™, Nicolas Weiss, 207640
Endoscopic radiofrequency ablation for the treatment of gastric antral vascular ectasia in cirrhotic patients: a bi-centric clinical and economical cost-effective analysis
EASL LiverTree™, Marco Senzolo, 207641
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
EASL LiverTree™, Hiroaki Takaya, 207645
Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A
EASL LiverTree™, Slim Fourati, 207659
NLRX1 and the p.Arg707Cys Variant in NLRX1 Affect Host Susceptibility of Hepatitis B Virus Infection in Huh7-NTCP cells
EASL LiverTree™, Liang Peng, 207661
DEAD-box helicases DDX5 and DDX17 areinvolved in the fine tuning of hepatitis B virus minichromosome transcriptional regulation
EASL LiverTree™, Fleur Chapus, 207663
Establishment of a method to compare antiviral effect of drug products by human hepatitis B virus infected humanized chimeric mice
EASL LiverTree™, Hatsune Enomoto, 207677
Identification of HBV genotypes and mutations associated to antiviral resistance and vaccine escape in serum and oral fluid samples from chronic hepatitis B patients
EASL LiverTree™, Moyra Machado Portilho, 207678
Identification of a stable HBV inter-genotype (A/G) recombinant strain in a guinean patient in 'grey zone' of treatment
EASL LiverTree™, Ana Isabel Gil, 207679
In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B
EASL LiverTree™, Lu Gao, 207680
Recapitulation of the complete HDV replication cycle in a novel hepatoma cell line allows for efficient antiviral compound evaluation
EASL LiverTree™, Florian Lempp, 207693
Proteomic analysis of hepatitis B virus cccDNA-specific associated proteins identifies crucial regulators of viral transcription and RNA processing
EASL LiverTree™, Barbara Testoni, 207694
Biogenesis and Function of Intracellular Hepatitis B e Antigen
EASL LiverTree™, Bidisha Mitra, 207695
Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate virus replication
EASL LiverTree™, Wenshi Wang, 207697
Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains
EASL LiverTree™, Athenaïs Gerber, 207712
Deep sequencing analysis highlights variations associated with HBeAg seroconversion in adolescents with chronic hepatitis B
EASL LiverTree™, Christophe Combet, 207713
Prevalence, Pathogenesis and Cross-species Transmission of A Novel Hepatitis E Virus from Bactrian Camels
EASL LiverTree™, Lin Wang, 207714
Hepatitis B virus entry in primary human hepatocytes initiates toll-like receptor 2-dependent immune signaling.
EASL LiverTree™, Ruth Broering, 207732
Probing new HBV therapies using fine needle aspirates to sample compartmentalised liver-resident immunity and hepatocytes
EASL LiverTree™, Upkar Gill, 207733
HBV-specific T cell responses in low replicating inactive carrier patients are independent of Hepatitis B surface antigen load
EASL LiverTree™, Upkar Gill, 207734
Performance of recomWell HEV and Wantai HEV in acute Hepatitis E and German blood donors
EASL LiverTree™, Friedhelm Struck, 207750
Ex vivo characterization of co-inhibitory molecules on MHC class II tetramer positive HCV-specific CD4+ T cells in HCV infection
EASL LiverTree™, Christin Ackermann, 207751
Association of PD1 and TIM3 Polymorphisms with HBV Susceptibility
EASL LiverTree™, chunhong huang, 207752
Preclinical mechanistic and efficacy evaluation of a novel small molecule TLR7 agonist RO7020531 for the treatment of chronic hepatitis B
EASL LiverTree™, Lu Gao, 207753
The Bile Acid Biome and Its Relationship to the Development and Severity of Alcoholic Hepatitis
EASL LiverTree™, Puneet Puri, 207769
Collagen proportionate área is an independent predictor of long term outcome in patients with alcoholic liver disease
EASL LiverTree™, Marta Guerrero-Misas, 207770
Lipofuscin is detected in early  stages of the disease in liver biopsies of patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Roberta Forlano, 207786
Stage-specific Benefits of Treatment Associated Fibrosis Regression in Patients with NASH: A Markov Modeling Approach
EASL LiverTree™, Jagpreet Chhatwal, 207787
Do patients with abnormal liver tests and nonalcoholic fatty liver disease get statins even when indicated?
EASL LiverTree™, Russell Rosenblatt, 207802
The effect of microvascular complications of diabetes on advanced fibrosis in nonalcoholic fatty liver disease
EASL LiverTree™, Russell Rosenblatt, 207803
Associations between Sarcopenia and Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in the United States
EASL LiverTree™, Karn Wijarnpreecha, 207804
The Platelet Count is Declining in American Adults in Parallel with an Increase in Risk Factors for Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Amandeep Singh, 207805
A Comprehensive Assessment of Serial Transient elastography in various Liver disease Etiologies at the Toronto Liver Centre (CASTLE-TLC)
EASL LiverTree™, Kerstina Boctor, 207819
Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients.
EASL LiverTree™, Amalia Gastaldelli, 207820
The triglycerides and glucose (TyG) index : a new marker associated with Non Alcoholic Steatohepatitis (NASH) and fibrosis in obese patients?
EASL LiverTree™, Stephanie Faure, 207821
Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars
EASL LiverTree™, Panu Luukkonen, 207822

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings